3 Stocks Soared, 3 Stocks Slumped

Moderna's stock fell 6.8% to $139.53 on August 27, 2026, despite analyst upgrades from Barclays, JP Morgan, and Wolfe Research. The average new price target of $101 is below the closing price, signaling caution. Trading volume surged to 11.0M shares, with a market cap of $55.7B. Analysts remain skeptical about the stock's valuation.

Moderna announced a $2.0B convertible notes offering, extending its cash runway to 2–2.5 years. The funds will support oncology pipeline, debt repayment, and dilution management. Revenue has collapsed 99% since FY2022, with Q2 2026 at $145M. Post-raise, cash is estimated at $3.5–3.8B, with a quarterly burn of $600–700M.

Moderna announced a $2B offering of convertible senior notes to increase financial flexibility. AstraZeneca and Amgen reported Phase 3 trial successes, as did Biokin. Additionally, news was shared about Takeda China and ProFound. According to the company, Moderna's offering aims to provide flexibility for future operations and investments.

Moderna is raising $2 billion in convertible debt following the success of its personalized cancer vaccine developed with Merck. The vaccine uses an algorithm to analyze tumor mutations and create a bespoke mRNA treatment. Some investors question the necessity of personalization. Meanwhile, a U.S. biotech crackdown on China could benefit European companies, and a rival drug failure may impact Alnylam's ATTR-CM franchise.

Moderna and Merck's phase 3 study shows promising results for their mRNA-based melanoma vaccine, intisimeran, when combined with Keytruda. The personalized treatment extends recurrence-free survival and reduces metastasis risk. Full data is awaited for further conclusions. The article also discusses potential profits and pricing concerns for the new cancer treatment.

MSCI is reviewing rules that could remove MicroStrategy from global equity indexes, focusing on companies primarily engaged in asset accumulation. MicroStrategy shares rose 35% in a week but are down 60% year-over-year. The review uses five financial metrics to assess eligibility, potentially affecting demand and capital access for MicroStrategy's Bitcoin purchases.